Page 4,697«..1020..4,6964,6974,6984,699..4,7104,720..»

Health Beat: Stem cells to cure sickle cell

Posted: Published on January 14th, 2014

ST. LOUIS - Sickle cell is a serious disease that causes pain, anemia, infection, organ damage and even stroke. Its the most common inherited blood disorder in the United States. The good news is bone marrow transplants can be a cure. The bad news is not every patient has a matching donor. Now, researchers are looking at a new way to offer more patients transplants. Madisyn Travis is like any other 9-year-old, but theres something that sets Madisyn apart. She has sickle cell, an inherited red blood cell disease. "It makes me feel bad, and sometimes I have to go to the hospital," Madisyn said. "It's really hard to see her life interrupted," said Denise Travis, Madisyn's mom. Soon, however, Madisyn will get a bone marrow transplant to cure her disease. Her little brother or sister are both matches, and one will be the donor. Madisyn is one of the lucky ones. Only 14 percent of patients have a matching sibling. "Ten years ago, we'd just tell them, 'Sorry, you have no family member. We cant transplant you,'" said Dr. Shalini Shenoy, professor of pediatrics and medical director, pediatric stem cell transplant program, Washington University School of Medicine, St. Louis … Continue reading

Comments Off on Health Beat: Stem cells to cure sickle cell

14 months after Stem Cell Therapy by Dr Harry Adelson for arthritis of the knee – Video

Posted: Published on January 14th, 2014

14 months after Stem Cell Therapy by Dr Harry Adelson for arthritis of the knee Nona discusses her outcome 14 months after Stem Cell Therapy by Dr Harry Adelson for arthritis of the knee http://www.docereclinics.com. By: Harry Adelson … Continue reading

Comments Off on 14 months after Stem Cell Therapy by Dr Harry Adelson for arthritis of the knee – Video

EMS 241- Paramedic Cardiology AP – Video

Posted: Published on January 14th, 2014

EMS 241- Paramedic Cardiology AP Cardiology AP. By: sucollege … Continue reading

Posted in Cardiology | Comments Off on EMS 241- Paramedic Cardiology AP – Video

How far can a Buddhist approach to biology take us?

Posted: Published on January 14th, 2014

Subjectivity is a key to the Buddhist approach to understanding the world (Image: Christophe Boisvieux/Corbis) In Buddhist Biology, David Barash highlights parallels between these empirical systems of thought, and suggests that together they can show us how to live AT FIRST glance, Buddhism and science seem natural bedfellows. Both seek essential truths about the world and the human condition and both set great store on their empirical approach. Yet the perception of a growing affiliation notwithstanding, at a deep level they are some way apart. The Buddhist approach to understanding is largely subjective: no one can meditate for you. And certain Buddhist principles, such as reincarnation, are blatantly unscientific. Science, on the other hand, requires verification and is often poor at quantifying personal experience (note the "hard problem" of consciousness). Above all, whereas science strives for objective knowledge, Buddhism offers an ethical framework in which to apply it. In his new book, Buddhist Biology, evolutionary psychologist David Barash is candid about this misalignment. His main aim, however, is to do for biology what other Buddhist-inclined writers have done for neuroscience, physics and psychology to highlight the parallels between the two disciplines, which he says "complement each other like a pair … Continue reading

Posted in Biology | Comments Off on How far can a Buddhist approach to biology take us?

Imaging of Petrous bone anatomy (Sep 2013) – Dr Mamdouh Mahfouz (In Arabic) – Video

Posted: Published on January 14th, 2014

Imaging of Petrous bone anatomy (Sep 2013) - Dr Mamdouh Mahfouz (In Arabic) Imaging of Petrous bone anatomy (Sep 2013) - Dr Mamdouh Mahfouz (In Arabic) By: Mamdouh Mahfouz … Continue reading

Posted in Anatomy | Comments Off on Imaging of Petrous bone anatomy (Sep 2013) – Dr Mamdouh Mahfouz (In Arabic) – Video

Small molecule shows promise as anti-cancer therapy

Posted: Published on January 13th, 2014

PUBLIC RELEASE DATE: 13-Jan-2014 Contact: Amy Mone amone1@jhmi.edu 410-614-2915 Johns Hopkins Medicine Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells. In a study described in the January 13 issue of Cancer-Cell, Marikki Laiho, M.D., Ph.D., and her colleagues say their work focused on the ability of a chemical dubbed BMH-21 to sabotage the transcription pathway RNA Polymerase pathway (POL I), shutting down the ability of mutant cancer genes to communicate with cells and replicate. Laiho's research linked the pathway to p53 gene activity. P53 is a tumor suppressor gene, a protein that regulates cell growth, and it is the most frequently mutated suppressor gene in cancer. Transcription pathways are the means by which certain proteins that direct cell division are put into action by cells. Uncontrolled cell division is a hallmark of cancer, and BMH-21 has demonstrated an ability to bind to the DNA of cancer cells and completely shut down this transcription pathway. "Without this transcription machinery, cancer cells cannot function," says Marikki Laiho, M.D., Ph.D., … Continue reading

Posted in Cell Medicine | Comments Off on Small molecule shows promise as anti-cancer therapy

DGAP-News: Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment …

Posted: Published on January 13th, 2014

DGAP-News: Prosensa Holding N.V. / Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment of Duchenne Muscular Dystrophy (DMD) 13.01.2014 / 14:00 --------------------------------------------------------------------- LEIDEN, Netherlands and LONDON, 2014-01-13 14:00 CET (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq:RNA) and GlaxoSmithKline (GSK) today announced that Prosensa has regained all rights from GSK to drisapersen and will retain rights to all other programs for the treatment of Duchenne Muscular Dystrophy (DMD). This transfer of rights represents the termination of the collaboration agreement between GSK and Prosensa executed in 2009. Prosensa will now have the full, unencumbered rights to continue the development of drisapersen as well as each of its DMD programs. The parties have agreed that Prosensa is well suited to continue the development of all of the DMD programs. Prosensa and GSK have also agreed to make certain data from the drisapersen studies available in due course to the scientific community for the purpose of furthering the general understanding of DMD. 'We are fully committed to our mission of developing innovative, RNA-based therapeutics to address unmet medical needs for patients with rare genetic disorders,' said Hans Schikan, Prosensa's Chief Executive Officer. 'Prosensa is now … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on DGAP-News: Prosensa Regains Rights to Drisapersen From GSK and Retains Rights to All Other Programs for the Treatment …

Prosensa Regains Rights to Drisapersen From GSK and Re.

Posted: Published on January 13th, 2014

(Nasdaq:RNA) and GlaxoSmithKline (GSK) today announcedthat Prosensa has regained all rights from GSK to drisapersen and will retainrights to all other programs for the treatment of Duchenne Muscular Dystrophy(DMD). This transfer of rights represents the termination of the collaborationagreement between GSK and Prosensa executed in 2009. Prosensa will now have the full, unencumbered rights to continue thedevelopment of drisapersen as well as each of its DMD programs. The parties have agreed that Prosensa is well suited to continue thedevelopment of all of the DMD programs. Prosensa and GSK have also agreed tomake certain data from the drisapersen studies available in due course to thescientific community for the purpose of furthering the general understanding ofDMD. 'We are fully committed to our mission of developing innovative, RNA-basedtherapeutics to address unmet medical needs for patients with rare geneticdisorders,' said Hans Schikan, Prosensa's Chief Executive Officer. 'Prosensa isnow in a favorable strategic position to advance the DMD portfolio, whichincludes drisapersen and five additional compounds, three of which arecurrently in clinical development. We will continue to work closely withpatient groups, investigators, academia and regulators to ensure that we doeverything we can to bring treatments to boys affected by DMD.' 'We have completed our review and … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Prosensa Regains Rights to Drisapersen From GSK and Re.

John M. Freeman, pediatric neurologist, dies at 80

Posted: Published on January 13th, 2014

John M. Freeman, a pediatric neurologist and medical ethicist who became a leading advocate of two long-abandoned therapies to control pediatric epilepsy that have shown to be effective in many cases, died Jan. 3 at Johns Hopkins Hospital in Baltimore. He was 80. The cause was cardiovascular disease, according to Johns Hopkins Medicine, the health and research institution that includes the hospital and Johns Hopkins University School of Medicine. Dr. Freemans questioning of established medical practices helped transform the treatment of pediatric epilepsy. He became a proponent of two long-abandoned therapies, which led to their revival and acceptance as effective treatments. One required a strict, unconventional high-fat diet, known as the ketogenic diet (KD). The other involved surgery to remove half the brain of children who were tormented by unremitting epileptic seizures. According to a Hopkins announcement of Dr. Freemans death: A high-fat, low-carbohydrate regimen that changes the bodys metabolism so that the brain gets its energy from ketones, a fat byproduct, rather than glucose, or sugar, initially was developed in the 1920s but largely abandoned once chemical anti-seizure medications such as Dilantin (phenytoin) were created in the 1930s. As recently as 1995, many physicians considered KD no longer a … Continue reading

Comments Off on John M. Freeman, pediatric neurologist, dies at 80

Autistic Help | Autism Treatment | Byonetics Autism Program …

Posted: Published on January 13th, 2014

My name is Jean Genet and I might be the most important autism specialist you will talk to concerning your childs autism. Why? Because I am one of the oldest members of the autistic community who is free of my symptoms of autism. I grew up autistic, conquered it, and developed the technology that helps your child to function free of the symptoms of autism. Brain Developmental Switches ByoNetics looks at the brain as a computer, a processor of information. The brain/computer needs to connect to its physical, emotional and speech software. It makes this connection through what has been identified as the brainsDevelopmental Switches. These Switches in the brainare crystalline structures in the neuro pathways, very much like fiber optics used in telephone communications. There are Seven MainDevelopmental Switchesthat connect the Brain/Computer to its mental, physical, emotional, and speech software. We believe that the chemical reactions in vaccines damages these SevenDevelopment Switches and turns them off. When these Switches are turned off the child cannot develop conversational speech. The child experiences hyperactivity, lack of mental focus, and cannot maintain emotional contact. Sensitivity to sound and tactile issues as it relates to the wearing of clothes are also present. Turning … Continue reading

Comments Off on Autistic Help | Autism Treatment | Byonetics Autism Program …

Page 4,697«..1020..4,6964,6974,6984,699..4,7104,720..»